Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
§ A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
§ Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
§ A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
§ A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
§ A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
§ A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
§ An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
§ A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
§ An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
§ An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
§ A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
§ A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
§ A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
§ A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Commonly Outsourced Business Operations
§ Active Pharmaceutical Ingredients (API)
§ Finished Dosage Formulations (FDF)
§ Types of Expression System
§ Mammalian
§ Microbial
§ Others
§ Company Size
§ Small
§ Mid-Sized
§ Large and Very Large
§ Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
§ Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
The report also features detailed transcripts of discussions held with the following experts:
§ Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
§ Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
§ Christian Bailly, Director of CDMO, Pierre Fabre
§ Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
§ David C Cunningham, Director Corporate Development, Goodwin Biotechnology
§ Dietmar Katinger, Chief Executive Officer, Polymun Scientific
§ Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
§ Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
§ Kevin Daley, Director Pharmaceuticals, Novasep
§ Mark Wright, Site Head, Grangemouth, Piramal Healthcare
§ Nicolas Grandchamp, R&D Leader, GEG Tech
§ Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
§ Sebastian Schuck, Head of Business Development, Wacker Biotech
§ Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
§ Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
§ Tim Oldham, Chief Executive Officer, Cell Therapies
Key companies covered in the report
§ 3P Biopharmaceuticals
§ Abzena
§ Albany Molecular Research
§ BioVectra
§ BioXcellence (Boehringer Ingelheim)
§ Celonic
§ Charles River Laboratories
§ ChemPartner
§ Cobra Biologics
§ CordenPharma
§ Cytovance Biologics
§ GE Healthcare
§ Goodwin Biotechnology
§ Grand River Aseptic Manufacturing
§ IDT Biologika
§ KBI BioPharma
§ Kemwell Biopharma
§ LFB Biomanufacturing
§ Meridian Life Science
§ Patheon
§ Pfizer CentreOne
§ PX'Therapeutics
§ Samsung BioLogics
§ Sanofi, CEPiA
§
Facebook Conversations